Skip to main content
    B

    BioCryst Pharmaceuticals Inc (BCRX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $7.45
    -0.16 (-2.10%)

    Market Cap: $1.96B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    BioCryst Pharmaceuticals Inc (BCRX) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    BioCryst Pharmaceuticals (BCRX) trades at 4.4x trailing earnings and 2.0x sales. Its P/S of 2.0x is below its 5-year median of 3.7x. Its forward P/E is 12.9x. The median P/E across 12 similar companies is 10.7x.

    Current Multiples

    Its forward P/E is above its trailing P/E, which implies earnings per share about 65.9% lower over the next year. PEG is left out because the growth rate behind it, P/E divided by PEG, is under 2% a year.

    MultipleValue
    P/E (trailing)4.4x
    Forward P/E12.9x
    Price to sales2.0x
    Price to FCF5.2x
    EV/FCF6.0x
    PEGN/A
    FCF yield19.2%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 81.1% below 10.6x.

    MultipleCurrent5-year median10-year median
    P/S2.0x3.7x10.6x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/S ranged from 1.9x in 2025 to 71.1x in 2020. 2025 was the lowest of those years.

    Year endPriceP/EP/SP/B
    2025$7.805.9x1.9xN/A
    2024$7.52N/A3.4xN/A
    2023$5.99N/A3.5xN/A
    2022$11.48N/A7.9xN/A
    2021$13.85N/A15.8xN/A
    2020$7.45N/A71.1xN/A
    2019$3.45N/A9.0x11.8x
    2018$8.07N/A39.4x18.0x
    2017$4.91N/A17.3x5.8x
    2016$6.33N/A17.7x295.9x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About BCRX

    What is BCRX's forward P/E ratio?

    BioCryst Pharmaceuticals has a forward P/E ratio of 12.9x.

    Is BCRX stock overvalued?

    GNG's valuation label for BCRX is Undervalued. Its P/E of 4.4x compares with a median of 10.7x across 12 similar companies.

    What is BCRX's price to sales ratio?

    BioCryst Pharmaceuticals has a price to sales ratio of 2.0x.